Related Experiment Video
Updated: Apr 20, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.1K
Castration-resistant prostate cancer: AUA guideline amendment
Michael S Cookson1, William T Lowrance1, Mohammad H Murad1
1American Urological Association Education and Research, Inc., Linthicum, Maryland.
The Journal of Urology
|December 3, 2014
Summary
This updated guideline incorporates new literature to improve treatment strategies for castration-resistant prostate cancer (CRPC). It emphasizes evidence-based recommendations and patient-centered care for managing CRPC.
Area of Science:
- Oncology
- Urology
- Clinical Guidelines
Background:
- Castration-resistant prostate cancer (CRPC) management is rapidly evolving.
- Previous guidelines were based on literature up to 2013.
- New evidence necessitates guideline updates.
Purpose of the Study:
- To update clinical guidelines for castration-resistant prostate cancer (CRPC) management.
- Incorporate newly published literature into existing recommendations.
- Provide a rational basis for CRPC patient care.
Main Methods:
- Systematic review and meta-analysis of published literature (1996-2013).
- Second literature search (Feb 2013-Feb 2014) identified 37 additional studies.
- Clinical principles and expert opinions supplemented evidence-based data.
Main Results:
- Guideline statements were amended based on new evidence.
- Radium-223 incorporation into CRPC treatment guidelines.
- Updated supporting text and new guideline statements were added.
Conclusions:
- Updated guidelines supplement the 2013 recommendations for CRPC treatment.
- Emphasizes using guidelines with systematic reviews and understanding patient goals.
- Continuous updates will occur as new literature emerges.
